Literature DB >> 24037624

Pathology and pathobiology of pulmonary hypertension.

Christophe Guignabert1, Peter Dorfmuller.   

Abstract

Pulmonary hypertension is a devastating, life-threatening disorder with no curative options, characterized by elevated pulmonary vascular resistance and secondary right ventricular failure. Although the etiologies of pulmonary arterial hypertension are multiple and its pathogenesis is complex, there is growing evidence that inflammation, endothelial dysfunction, aberrant vascular wall cell proliferation, as well as mutations in the bone morphogenetic protein receptor type 2 gene play a crucial role in triggering pathological vascular remodeling. The present article outlines the current understanding of this disease from the point of view of pathology and pathobiology. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2013        PMID: 24037624     DOI: 10.1055/s-0033-1356496

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  28 in total

1.  Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.

Authors:  Gexiang Cai; Jingjing Liu; Meibin Wang; Lihuang Su; Mengsi Cai; Kate Huang; Xiuchun Li; Manxiang Li; Liangxing Wang; Xiaoying Huang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

Review 2.  Sex differences in the pulmonary circulation: implications for pulmonary hypertension.

Authors:  Yvette N Martin; Christina M Pabelick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-07       Impact factor: 4.733

Review 3.  Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Authors:  Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

4.  Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Authors:  Christophe Guignabert; Carole Phan; Andrei Seferian; Alice Huertas; Ly Tu; Raphaël Thuillet; Caroline Sattler; Morane Le Hiress; Yuichi Tamura; Etienne-Marie Jutant; Marie-Camille Chaumais; Stéphane Bouchet; Benjamin Manéglier; Mathieu Molimard; Philippe Rousselot; Olivier Sitbon; Gérald Simonneau; David Montani; Marc Humbert
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

5.  Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension.

Authors:  Toshio Suzuki; Erica J Carrier; Megha H Talati; Anandharajan Rathinasabapathy; Xinping Chen; Rintaro Nishimura; Yuji Tada; Koichiro Tatsumi; James West
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-09-21       Impact factor: 5.464

Review 6.  The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.

Authors:  Yasunobu Hayabuchi
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

7.  Cerivastatin Nanoliposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Young Lee; S Balakrishna Pai; Ravi V Bellamkonda; David H Thompson; Jaipal Singh
Journal:  J Pharmacol Exp Ther       Date:  2018-04-25       Impact factor: 4.030

Review 8.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

9.  Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1/p27Kip1 signaling pathway.

Authors:  Yang Song; Yonghong Zhang; Haoxiang Jiang; Yanting Zhu; Lu Liu; Wei Feng; Lan Yang; Yibin Wang; Manxiang Li
Journal:  FEBS Open Bio       Date:  2015-08-12       Impact factor: 2.693

Review 10.  Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate.

Authors:  Kelley L Colvin; Melanie J Dufva; Ryan P Delaney; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Front Pediatr       Date:  2014-02-03       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.